Navigation Links
bioTheranostics' Breast Cancer Index(SM) Predicts Risk for Late Recurrence in Early Stage ER-Positive Breast Cancer Patients
Date:12/10/2010

SAN DIEGO, Dec. 10, 2010 /PRNewswire/ -- bioTheranostics, a bioMerieux company that develops innovative oncology diagnostic tests to support targeted disease management, announced today new findings from a clinical study evaluating the company's Breast Cancer Index (BCI) molecular oncology test. Data from the study were presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

The company also announced that the Breast Cancer Index is now available to provide quantitative assessment of the risk of distant disease recurrence.  The BCI risk assessment  is based on data from a recently completed large, randomized, retrospective trial.(1)

"The results presented in San Antonio today become part of a substantial and growing body of data supporting the clinical value of the Breast Cancer Index," said Richard Ding, chief executive officer of bioTheranostics. "We are pleased to make this valuable test available to oncologists and pathologists in an enhanced format with clinical data specific for late breast cancer recurrence."

The Breast Cancer Index is a combination of HOXB13:IL17BR (H/I) and Molecular Grade Index (MGI), biomarkers that improve risk stratification in patients with estrogen receptor (ER)-positive, lymph-node negative breast cancer. This population represents the majority of breast cancers diagnosed each year.

Data presented today are from the MA.17 study, a previously conducted, randomized prospective trial.  This study evaluated the role of adjuvant endocrine therapy with letrozole in reducing the risk of recurrence and improving disease-free survival among women with breast cancer who completed five years of tamoxifen therapy. As part of the study, Massachusetts General Hospital researchers Paul Goss, MD, PhD and Dennis Sgroi, MD retrospectively evaluated the ability of the Breast Cancer Index to distinguish those patients at risk of late recurrence and those who
'/>"/>

SOURCE bioTheranostics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AltheaDx and Compendia Bioscience Launch the Breast Cancer Segregation Panel™
2. Combined Sales of Seven Emerging Therapies for Breast Cancer, Including Drugs From Sanofi-Aventis and AstraZeneca, Will Total Nearly $5 Billion by 2019
3. Reportlinker Adds Breast Cancer Drug Futures
4. LCS Constructors, Inc. Supports the Cure and Breast Cancer Awareness Month
5. Leading Journal Turns Up the Heat on Cutting-Edge Breast Cancer Treatment
6. K-State Research Team Investigates Mutated Genes Role in Breast Cancer
7. Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting
8. Agendia Presents Broad Array of Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO 2010 Annual Meeting
9. Huiheng Medical, Inc. Announces Agreement to Acquire the ClearPath (TM) Breast Brachytherapy System
10. Abviva Details Patent Information for its Breast Cancer Risk Assessment Technology
11. Abviva Announces Further Patent Issuance for Technology Used in Breast Cancer Diagnostics and Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... PA (PRWEB) September 02, 2014 ... a new highly efficient, cost effective approach to ... Patent No. 8,820,265 by the U.S. Patent and ... to Opertech. , “Opertech’s taste evaluation ... the first automated high throughput system for rapid ...
(Date:9/2/2014)... Md. , Sept. 2, 2014  Synthetic ... novel anti-infective biologic and drug candidates targeting specific ... today positive results from its final preclinical toxicology ... Administration (FDA) guidance, this bridging study was required ... candidate designed to prevent the devastating effects of ...
(Date:9/2/2014)... Massachusetts , September 2, 2014 ... to BioData,s research and lab management services  ... management service, is pleased to announce the appointment of ... Culot most recently served as VP Marketing and Business ... life science research and clinical applications. Previously, ...
(Date:9/1/2014)... September 01, 2014 The Collaborative ... Diagnostics report provides comprehensive understanding and unprecedented access ... into by the worlds leading life science companies. ... analysis of how and why companies enter collaborative ... prospective partner’s negotiated deals terms provides critical insight ...
Breaking Biology Technology:Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5Louis Culot Appointed as BioData's CEO 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 4
... life sciences ... ... an,agreement to acquire Recombinant Capital, Inc. (Recap), a leading life,sciences subscription ... database that provides more than 1,500,subscribers with access to over 20 ...
... 16 Scimitar Equity, LLC issues a review ... Pipeline of Niche, Cancer Therapies with Billion Dollar ... http://www.scimitarequity.com ., VioQuest Pharmaceuticals is a ... leader in the successful development of,novel drug therapies ...
... from PAREXEL,International Corporation (Nasdaq: PRXL ), a ... than 20,sessions at the Drug Information Association (DIA) ... 22 -- 26, 2008 at the Boston Convention ... global,headquarters office. PAREXEL experts will address key industry ...
Cached Biology Technology:Deloitte Agrees to Acquire Recombinant Capital, A Leading Life Sciences Subscription Database and Advisory Services Firm 2Scimitar Equity, LLC Initiates Coverage Review of VioQuest Pharmaceuticals, Inc. 2PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting 2PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting 3PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting 4PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting 5PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting 6PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting 7
(Date:9/2/2014)... professional baseball pitchers with poor core stability are more likely ... because of injury than are pitchers who have good control ... the study, 347 pitchers were assessed for lumbopelvic control during ... they raised a leg to step up were up to ... cumulative, not consecutive during the season than were ...
(Date:9/2/2014)... to prevent Type 2 diabetes, don,t get your hopes up. ... The FASEB Journal , suggests that you don,t ... study compared genetically identical twins-one heavier and one leaner-and found ... those related to Type 2 diabetes, were found in both ... the onset of this type of diabetes is largely influenced ...
(Date:9/2/2014)... the battle between our immune systems and cholera bacteria, ... known as phages. In a new study, researchers from ... National Public Health Laboratory, and elsewhere, report that phages ... in order to survive. Importantly, the study published ... escape from phage predation occurs during human infection. , ...
Breaking Biology News(10 mins):In pro baseball pitchers, weak core linked to more missed days 2In pro baseball pitchers, weak core linked to more missed days 3What you eat and not just the number of calories, is a significant factor in diabetes risk 2War between bacteria and phages benefits humans 2War between bacteria and phages benefits humans 3
... (www.ucr.edu) -- Twenty-one undergraduate students in the UC Riverside Bourns ... researching everything from water quality to wildfires to materials that ... lot of opportunities to get involved with research," said Erika ... part in the Summer Bridge program. "This is the reason ...
... Tampa, Fla. (July 26, 2010) Australian ... "reprogrammed" adult mouse fat cells and neural cells to ... of different cells (pluripotency). The cells, called "induced pluripotent ... occurring pluripotent stems cells, such as embryonic stem cells, ...
... which a herpes virus invades cells has remained a mystery ... University of Pennsylvania reveals the unusual structure of a key ... to invade cells. The new map details an essential ... a new target for antiviral drugs. The research was ...
Cached Biology News:Undergrad engineers research everything from water quality to wildfires this summer 2Scientists 'reprogram' mouse fat cells into clinically useful stem cells 2A collaboration solves the herpes virus protein structure providing new drug therapy directions 2A collaboration solves the herpes virus protein structure providing new drug therapy directions 3